8-KMaterial AgreementsRegulation FDExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Material Agreement (Jul 3, 2024)

Filed July 3, 2024For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) has announced a significant strategic move through an Equity Purchase Agreement to acquire LifeLabs Inc. and BPC LP. This transaction, valued at approximately CAD 1.35 billion (USD 985 million) including net debt, involves purchasing all shares and partnership interests of the Canadian diagnostic information and digital health connectivity providers. The acquisition is expected to be completed by the end of 2024, subject to customary closing conditions, including regulatory approvals under the Competition Act (Canada) and the Investment Canada Act, as well as consents from key customers. This move represents a material expansion for Quest Diagnostics into the Canadian market, aiming to enhance its service offerings and market presence. Investors should monitor the satisfaction of the closing conditions, as failure to obtain necessary approvals could result in a termination fee for Quest Diagnostics. The company has also entered into restrictive covenants regarding the operations of the Target Entities during the interim period, underscoring the definitive nature of the agreement.

Key Highlights

  • 1Quest Diagnostics enters into an Equity Purchase Agreement to acquire LifeLabs Inc. and BPC LP, which provide laboratory diagnostic information and digital health connectivity systems in Canada.
  • 2The total purchase price is approximately CAD 1.35 billion (USD 985 million), including net debt, to be paid in cash.
  • 3The transaction is anticipated to close by the end of 2024, pending satisfaction of closing conditions.
  • 4Key closing conditions include obtaining consents from certain LifeLabs customers and clearance under Canadian competition and investment regulations.
  • 5Quest Diagnostics guarantees the obligations of its subsidiary, the buyer, under the agreement.
  • 6A termination fee may be payable if approvals are not obtained within the agreed timeframe, provided the sellers are not in breach.
  • 7The company has also announced this acquisition via a press release dated July 3, 2024.

Frequently Asked Questions

This 8-K filing announces Quest Diagnostics Incorporated's entry into a Material Definitive Agreement to acquire LifeLabs Inc. and BPC LP, detailing the terms and conditions of the proposed transaction.

The acquisition is valued at approximately CAD 1.35 billion (USD 985 million), including net debt, and will be financed through a cash purchase price.

Key conditions include obtaining consents from certain LifeLabs customers, clearance under the Competition Act (Canada), and no prohibition under the Investment Canada Act. The transaction is also subject to customary closing conditions.

The proposed transaction is expected to close by the end of 2024, subject to the satisfaction of all closing conditions and necessary approvals.